Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Free Report) – Equities researchers at HC Wainwright dropped their Q2 2024 earnings estimates for shares of Eton Pharmaceuticals in a note issued to investors on Monday, July 3rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of $0.02 for the quarter, down […]
Eton Pharmaceuticals (NASDAQ:ETON – Free Report) had its price objective trimmed by HC Wainwright from $10.00 to $9.00 in a research note issued to investors on Monday, The Fly reports. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q2 2024 earnings at $0.02 EPS, Q3 2024 earnings at $0.03 EPS, Q4 2024 earnings at $0.06 […]
Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Rating) was the recipient of a large growth in short interest during the month of May. As of May 31st, there was short interest totalling 562,700 shares, a growth of 6.1% from the May 15th total of 530,400 shares. Approximately 2.5% of the shares of the stock are sold […]
Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Rating) was the target of a significant decline in short interest in May. As of May 15th, there was short interest totalling 530,400 shares, a decline of 9.7% from the April 30th total of 587,500 shares. Approximately 2.4% of the shares of the stock are sold short. Based on […]
Opaleye Management Inc. lowered its stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON – Get Rating) by 13.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,170,000 shares of the company’s stock after selling 351,000 shares during the quarter. Eton Pharmaceuticals […]